202057-76-9
|
|
|
- CAS号:
- 202057-76-9
- 英文名:
- manitimus
- 英文别名:
- FK778;manitimus;Manitimus（FK778）;2-Hepten-6-ynamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-, (Z)-;2-Hepten-6-ynamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-
- 中文名:
- 202057-76-9
- 中文别名:
- 化合物 T11941
- CBNumber:
- CB31508603
- 分子式:
- C15H11F3N2O2
- 分子量:
- 308.26
- MOL File:
- 202057-76-9.mol
|
|
|
202057-76-9化学性质
-
沸点:
-
489.4±45.0 °C(Predicted)
-
|
-
密度:
-
1.382±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO: 250 mg/mL (811.00 mM)
-
|
-
酸度系数(pKa):
-
5.23±0.50(Predicted)
-
|
202057-76-9性质、用途与生产工艺
Manitimus 是一种 dehydroorotate dehydrogenase 的抑制剂，同时为有效的免疫抑制药。
In the Manitimus-treated rats, there is a dose-related, differential effect: mean survival is 15.7 days in group 4 (Manitimus 5 mg/kg), 19.1 days in group 5 (Manitimus 10 mg/kg) and 25.4 days in group 6 (Manitimus 20 mg/kg). Manitimus (15 mg/kg, p.o.) results in a significant decrease in neointimal area and percentage of stenosis versus the control rats, and diminishes the effect that CMV infection results in a significant increase in intimal and medial cross-sectional area and medial wall thickness of the vein grafts.
202057-76-9
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-101603 | 202057-76-9
Manitimus | 202057-76-9 | 1mg | 2000元 |
| 2024/04/30 | HY-101603 | 202057-76-9
Manitimus | 202057-76-9 | 5mg | 4000元 |
202057-76-9, 202057-76-9 相关搜索:
- 制剂-抑制剂
- 化合物 T11941
- 202057-76-9
- Manitimus（FK778）
- 2-Hepten-6-ynamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-
- FK778
- 2-Hepten-6-ynamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-, (Z)-
- manitimus